everolimus
AssetSmall moleculeAlso Certican, Certican®, EVR+rCNI, Everolimus (Certican)
Selective inhibitor of mTOR complex 1 (mTORC1)
- Stage
- Approved
- Modality
- Small molecule
- Target
- Autophagy
- Indications
- 109
- Trials
- 641
- Developers
- 3
Indications
109Advanced breast cancer
Approvedema.europa.eu7 Oct 2026
Angiomyolipoma
Approvedema.europa.eu7 Oct 2026
Breast neoplasm
Approvedema.europa.eu7 Oct 2026
106 more
- Targets and what it contains2
- Owner and partners3
- Trials641
- Evidence for its targets2
- Competitors12
- Aging relevance4
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 92 sources